OSI Sues Teva, Mylan Over Cancer Drug Patents
OSI Pharmaceuticals Inc. has targeted Teva Pharmaceuticals USA Inc. and Mylan Pharmaceuticals Inc. in patent infringement litigation to stop them from taking steps to market a generic version of cancer treatment...To view the full article, register now.
Already a subscriber? Click here to view full article